Lipocine Updates Corporate Presentation in Recent 8-K Filing
Lipocine Inc. has disclosed in its recent 8-K filing with the Securities and Exchange Commission that the company has made changes to its corporate presentation utilized during engagements with investors, analysts, and other relevant parties. The updated presentation has been officially submitted as Exhibit 99.1 alongside the filing. Based on the filing, Lipocine Inc., a […]
Lipocine Inc. has disclosed in its recent 8-K filing with the Securities and Exchange Commission that the company has made changes to its corporate presentation utilized during engagements with investors, analysts, and other relevant parties. The updated presentation has been officially submitted as Exhibit 99.1 alongside the filing. Based on the filing, Lipocine Inc., a […]
